MA29147B1 - Formes cristallines d'hydrochlorure de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine - Google Patents
Formes cristallines d'hydrochlorure de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepineInfo
- Publication number
- MA29147B1 MA29147B1 MA30070A MA30070A MA29147B1 MA 29147 B1 MA29147 B1 MA 29147B1 MA 30070 A MA30070 A MA 30070A MA 30070 A MA30070 A MA 30070A MA 29147 B1 MA29147 B1 MA 29147B1
- Authority
- MA
- Morocco
- Prior art keywords
- tetrahydro
- chloro
- methyl
- crystalline forms
- benzazepine hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES FORMES CRISTALLINES DE (R)-8-CHLORO-1-MÉTHYL-2,3,4,5-TÉTRAHYDRO-1H-3-BENZAZÉPINE, DES COMPOSITIONS CONTENANT CES FORMES, AINSI QUE DES PRÉPARATIONS ET DES UTILISATIONS DE CELLES-CI.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63822104P | 2004-12-21 | 2004-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29147B1 true MA29147B1 (fr) | 2008-01-02 |
Family
ID=36602366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30070A MA29147B1 (fr) | 2004-12-21 | 2007-07-12 | Formes cristallines d'hydrochlorure de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine |
Country Status (29)
Country | Link |
---|---|
US (4) | US8168624B2 (fr) |
EP (3) | EP1838677B1 (fr) |
JP (3) | JP5270167B2 (fr) |
KR (1) | KR101281919B1 (fr) |
CN (2) | CN101084193B (fr) |
AT (1) | ATE442359T1 (fr) |
AU (1) | AU2005318959B2 (fr) |
BR (1) | BRPI0519726B8 (fr) |
CA (1) | CA2589988C (fr) |
CU (1) | CU20070138A7 (fr) |
CY (1) | CY1109599T1 (fr) |
DE (1) | DE602005016603D1 (fr) |
DK (1) | DK1838677T3 (fr) |
EA (2) | EA201200954A1 (fr) |
ES (1) | ES2332009T3 (fr) |
HK (2) | HK1102812A1 (fr) |
HR (1) | HRP20090640T1 (fr) |
IL (1) | IL183844A (fr) |
MA (1) | MA29147B1 (fr) |
ME (1) | ME01090B (fr) |
NI (1) | NI200700160A (fr) |
NZ (2) | NZ555981A (fr) |
PL (1) | PL1838677T3 (fr) |
PT (1) | PT1838677E (fr) |
RS (1) | RS50996B (fr) |
SI (1) | SI1838677T1 (fr) |
TN (1) | TNSN07235A1 (fr) |
WO (1) | WO2006069363A2 (fr) |
ZA (1) | ZA200705125B (fr) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
EP2189448B1 (fr) | 2003-06-17 | 2014-01-29 | Arena Pharmaceuticals, Inc. | Procédés de séparation de racemates de 3-Benzazepines |
NZ578503A (en) | 2003-06-17 | 2011-02-25 | Arena Pharm Inc | Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
EP1838677B1 (fr) | 2004-12-21 | 2009-09-09 | Arena Pharmaceuticals, Inc. | Formes cristallines d'hydrochlorure de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine |
CA2588941A1 (fr) * | 2004-12-23 | 2006-07-06 | Arena Pharmaceuticals, Inc. | Compositions renfermant un modulateur des recepteurs 5ht2c et procedes d'utilisation correspondants |
DE602006008323D1 (de) | 2005-09-01 | 2009-09-17 | Lilly Co Eli | 6-substituierte- 2,3,4,5-tetrahydro-1h-benzoädüazepine als 5-ht2c-rezeptoragonisten |
SI1926712T1 (sl) | 2005-09-01 | 2010-01-29 | Lilly Co Eli | 6-substituirani 2,3.4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja |
WO2007028083A2 (fr) | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | Utilisation de 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines comme agonistes des recepteurs 5-ht2c |
CA2619450C (fr) | 2005-09-01 | 2013-10-22 | Eli Lilly And Company | 2,3,4,5-tetrahydro-1h-benzo[d]azepines substituees par un heterocycle a liaison 6-n en tant qu'agonistes de recepteur 5-ht2c |
CN101466684B (zh) * | 2006-04-03 | 2012-06-20 | 艾尼纳制药公司 | 8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的制备工艺和其相关中间体 |
WO2007140213A1 (fr) | 2006-05-26 | 2007-12-06 | Forest Laboratories Holdings Limited | Dérivés de pyridoazépines |
CA2670285A1 (fr) | 2006-12-05 | 2008-06-12 | Arena Pharmaceuticals, Inc. | Procedes de preparation de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine et intermediaires de celle-ci |
CN102015591B (zh) | 2008-03-04 | 2014-01-29 | 艾尼纳制药公司 | 制备与5-ht2c激动剂(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓相关的中间体的方法 |
US8952197B2 (en) | 2009-06-18 | 2015-02-10 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
WO2011153206A1 (fr) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Procédés pour la préparation d'agonistes du récepteur 5-ht2c |
KR20140091458A (ko) | 2010-09-01 | 2014-07-21 | 아레나 파마슈티칼스, 인크. | 신장 손상을 갖는 개체에 대한 로카세린의 투여 |
AU2011296003B2 (en) * | 2010-09-01 | 2015-11-12 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-HT2C agonist useful for weight management |
CN103189358A (zh) * | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的快速溶解剂型 |
KR20130101524A (ko) * | 2010-09-01 | 2013-09-13 | 아레나 파마슈티칼스, 인크. | 5-ht2c 아고니스트의 비-흡습성 염 |
US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
AU2015268758B2 (en) * | 2010-09-01 | 2017-08-24 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-HT2c agonists useful for weight management |
CN103189359A (zh) * | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的光学活性酸盐 |
CA2886875A1 (fr) * | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Procede de gestion du poids |
EP2868656A1 (fr) | 2013-11-05 | 2015-05-06 | LEK Pharmaceuticals d.d. | Hydrochlorure de lorcasérine amorphe stabilisé |
IN2013MU03565A (fr) * | 2013-11-13 | 2015-07-24 | Cadila Healthcare Ltd | |
CN104936947B (zh) * | 2013-12-27 | 2017-03-08 | 杭州普晒医药科技有限公司 | 氯卡色林盐及其晶体、其制备方法和用途 |
EP2924024A3 (fr) | 2014-03-21 | 2016-01-20 | Medichem, S.A. | Formes solides de composés d'hydrochlorure de lorcaserin |
WO2015161730A1 (fr) * | 2014-04-21 | 2015-10-29 | 杭州普晒医药科技有限公司 | Cristal eutectique de lorcasérine et procédé de préparation, composition pharmaceutique le contenant et utilisation |
WO2015170346A1 (fr) | 2014-05-09 | 2015-11-12 | Council Of Scientific & Industrial Research | Procédé de préparation de 8-chloro-1-méthyl -2,3,4,5-tétrahydro-1h-benzo[d]azépine et de ses énantiomères |
TW201618787A (zh) | 2014-10-30 | 2016-06-01 | 艾尼納製藥公司 | 組合物及方法 |
CN104829532A (zh) * | 2015-05-15 | 2015-08-12 | 浙江理工大学 | 一种制备绿卡色林盐酸盐单晶的方法 |
CN104844512B (zh) * | 2015-05-15 | 2017-03-29 | 东北制药集团股份有限公司 | 一种绿卡色林盐酸盐半水合物晶型的制备方法 |
CN107708701A (zh) * | 2015-06-30 | 2018-02-16 | 纽拉德有限公司 | 新颖呼吸控制调节化合物以及其制备和使用方法 |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
CN116270646A (zh) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
EP3210975A1 (fr) | 2016-02-24 | 2017-08-30 | Enantia, S.L. | Co-cristaux de lorcaserine |
CN106478506B (zh) * | 2016-09-30 | 2019-03-15 | 山东科兴生物制品有限公司 | 半水绿卡色林盐酸盐的制备方法 |
CN112704670B (zh) * | 2021-01-08 | 2022-07-15 | 安徽中医药大学 | 一种盐酸氯卡色林渗透泵控释制剂及其制备方法 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH498122A (de) | 1968-02-09 | 1970-10-31 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates |
CH481110A (de) | 1967-02-17 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen |
CH500194A (de) | 1968-02-15 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von Tetrahydroazepinderivaten |
CA974989A (en) | 1968-03-11 | 1975-09-23 | Wallace And Tiernan Inc. | Process for preparing 1,2,4,5-tetrahydro-3h,3-benzazepines and products obtained thereby |
US4233217A (en) | 1968-03-11 | 1980-11-11 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines |
FR7736M (fr) | 1968-09-02 | 1970-03-09 | ||
US3716639A (en) | 1970-03-11 | 1973-02-13 | Ciba Geigy Corp | Anorexigenic tetrahydrobenzazepines |
US3795683A (en) | 1970-08-19 | 1974-03-05 | Hoffmann La Roche | 2,3,4,5-tetrahydro-1h-3-benzazepines |
LU65954A1 (fr) | 1972-08-25 | 1974-03-07 | ||
US4210749A (en) | 1974-11-12 | 1980-07-01 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines |
US4111957A (en) | 1977-02-02 | 1978-09-05 | Smithkline Corporation | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
US4108989A (en) | 1977-04-01 | 1978-08-22 | Smithkline Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones |
CA1090797A (fr) | 1978-06-20 | 1980-12-02 | Kenneth G. Holden | Composes a base de 2,3,4,5-tetrahydro-1h-3- benzazepine a substitution en 1 par un groupement thienyle ou un groupement furyle |
AU515236B2 (en) | 1978-06-26 | 1981-03-26 | Smithkline Corporation | Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives |
ZA792785B (en) | 1978-07-07 | 1980-08-27 | Smithkline Corp | Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines |
DE3272044D1 (de) | 1981-11-27 | 1986-08-21 | Smithkline Beckman Corp | 3-benzazepines as alpha-2 antagonists |
FR2525603A1 (fr) | 1982-04-27 | 1983-10-28 | Adir | Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique |
US4988690A (en) | 1982-06-14 | 1991-01-29 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof |
US4541954A (en) | 1984-09-05 | 1985-09-17 | Smithkline Beckman Corporation | Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
US4762845A (en) | 1986-05-21 | 1988-08-09 | Abbott Laboratories | 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids |
EP0285287A3 (fr) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | Emploi de 3-benzazépines pour le traitement des troubles de la mobilité gastro-intestinale |
US5015639A (en) | 1987-03-27 | 1991-05-14 | Schering Corporation | Substituted benzazepines, their preparation and pharmaceutical compositions containing them |
ZA882080B (en) | 1987-03-27 | 1989-04-26 | Schering Corp | Substituted benzazepines,their preparation and pharmaceutical compositions containing them |
WO1988007858A1 (fr) | 1987-04-09 | 1988-10-20 | Smithkline Beckman Corporation | Benzazepines substituees en position 3 par un groupe sulfinyle et sulfonyle |
US5422355A (en) | 1989-06-02 | 1995-06-06 | John Wyeth & Brother, Limited | Composition for treating depression with (N-heteroaryl)alkylamines |
US5178786A (en) | 1989-08-04 | 1993-01-12 | The Lubrizol Corporation | Corrosion-inhibiting compositions and functional fluids containing same |
WO1991019698A1 (fr) | 1990-06-15 | 1991-12-26 | Schering Corporation | Benzazepines substituees de 8-alkyle inferieur-5-cycloalkyle ou 5-cycloalcenyle et compositions pharmaceutiques les contenant |
US5275915A (en) | 1991-06-05 | 1994-01-04 | Dainippon Ink And Chemicals, Inc. | Developer for light-sensitive material |
KR940701258A (ko) | 1991-06-21 | 1994-05-28 | 피터 죤 기딩즈 | 문맥압 항진증 및 편두통의 치료를 위한 테트라하이드로벤즈아제핀 유도체의 용도 |
EP0558824A1 (fr) | 1992-02-04 | 1993-09-08 | Duphar International Research B.V | Procédé pour la préparation d'aminoalcools vicinaux et de leurs dérivés protégés optiquement actifs |
JPH05339263A (ja) | 1992-06-08 | 1993-12-21 | Wakunaga Pharmaceut Co Ltd | ジヒドロピリジン誘導体 |
JPH06298746A (ja) | 1993-04-19 | 1994-10-25 | Showa Denko Kk | 環状イミド酸エステルの製造法 |
ZA944513B (en) | 1993-06-23 | 1996-01-16 | Cambridge Neuroscience Inc | Sigma receptor ligands |
US5387685A (en) | 1993-07-16 | 1995-02-07 | American Cyanamid Co | MDR reversal agents |
GB9322976D0 (en) | 1993-11-08 | 1994-01-05 | Pfizer Ltd | Therapeutic agents |
DE4419315A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie |
DE4419246A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie |
DE4419247A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie |
DE4427838A1 (de) | 1994-08-05 | 1996-02-08 | Thomae Gmbh Dr K | Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE4429079A1 (de) | 1994-08-17 | 1996-02-22 | Thomae Gmbh Dr K | Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
JPH08134048A (ja) | 1994-11-08 | 1996-05-28 | Sumitomo Chem Co Ltd | オキサゾリン類の製造法 |
GB9508622D0 (en) | 1995-04-28 | 1995-06-14 | Pfizer Ltd | Therapeutic agants |
JPH0930960A (ja) | 1995-07-18 | 1997-02-04 | Takasago Internatl Corp | 真菌感染症治療剤 |
JPH0987258A (ja) | 1995-09-28 | 1997-03-31 | Sumitomo Chem Co Ltd | オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法 |
CA2190708A1 (fr) | 1995-12-08 | 1997-06-09 | Johannes Aebi | Derives de substitution aminoalkyles de composes benzo-heterocycliques |
US5892116A (en) | 1996-01-03 | 1999-04-06 | Georgetown University | Gelators |
US5925651A (en) | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
EP0920417A4 (fr) | 1996-08-15 | 1999-12-29 | Smithkline Beecham Corp | Antagonistes du recepteur de l'il-8 |
JP2001514631A (ja) | 1997-03-07 | 2001-09-11 | ノボ ノルディスク アクティーゼルスカブ | 4,5,6,7−テトラヒドロ−チエノ[3,2−c]ピリジン誘導体類、それらの製造方法及び使用 |
AUPP020297A0 (en) | 1997-11-05 | 1997-11-27 | University Of Melbourne, The | A novel receptor, and compounds which bind thereto |
EP0987235B1 (fr) | 1998-08-25 | 2003-03-12 | MERCK PATENT GmbH | Procédé pour la conversion d'arènes ou d'alkènes avec des iodoalkènes, des aryliodides ou des sels arènediazonium |
EP1074549B1 (fr) | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tétrahydro-benzo(d)azépines et leurs utilisations en tant qu'antagonistes du récepteur de glutamate métabotropique |
DE60006618T2 (de) | 1999-08-06 | 2004-09-23 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten |
DE10003708A1 (de) | 2000-01-28 | 2001-08-02 | Solvent Innovation Gmbh | Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form |
WO2002040471A2 (fr) | 2000-11-14 | 2002-05-23 | Smithkline Beecham P.L.C. | Derives de tetrahydrobenzazepine utiles en tant que modulateurs des recepteurs d3 de la dopamine (agents antipsychotiques) |
GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
JPWO2002074746A1 (ja) | 2001-03-16 | 2004-07-08 | 山之内製薬株式会社 | ベンゾアゼピン誘導体 |
DE10119278C1 (de) | 2001-04-20 | 2002-10-02 | Merck Patent Gmbh | Verfahren zur Herstellung von Fluoralkylphosphaten |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
AU2002356525A1 (en) | 2001-09-24 | 2003-04-07 | Elan Pharmaceuticals, Inc. | Substituted amines for the treatment of neurological disorders |
CA2473740A1 (fr) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Procedes pour traiter des pathologies associees a un recepteur d'edg |
NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
EP2189448B1 (fr) * | 2003-06-17 | 2014-01-29 | Arena Pharmaceuticals, Inc. | Procédés de séparation de racemates de 3-Benzazepines |
NZ578503A (en) | 2003-06-17 | 2011-02-25 | Arena Pharm Inc | Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
WO2005042491A1 (fr) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Derives de benzazepine et methodes de prophylaxie ou traitement de maladies associees au recepteur 5ht2c |
US20070275949A1 (en) | 2003-10-22 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases |
US20080269282A1 (en) | 2004-08-02 | 2008-10-30 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
WO2006043710A1 (fr) | 2004-10-19 | 2006-04-27 | Reverse Proteomics Research Institute Co., Ltd. | Protéine cible et gène cible pour le développement de médicaments et procédé de recherche par criblage |
EP1838677B1 (fr) | 2004-12-21 | 2009-09-09 | Arena Pharmaceuticals, Inc. | Formes cristallines d'hydrochlorure de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine |
CA2588941A1 (fr) | 2004-12-23 | 2006-07-06 | Arena Pharmaceuticals, Inc. | Compositions renfermant un modulateur des recepteurs 5ht2c et procedes d'utilisation correspondants |
CN101466684B (zh) | 2006-04-03 | 2012-06-20 | 艾尼纳制药公司 | 8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的制备工艺和其相关中间体 |
JP5339263B2 (ja) | 2007-07-26 | 2013-11-13 | コクヨ株式会社 | 引き戸の取付構造、引き戸及び収納装置 |
-
2005
- 2005-12-20 EP EP05855526A patent/EP1838677B1/fr active Active
- 2005-12-20 JP JP2007547060A patent/JP5270167B2/ja active Active
- 2005-12-20 RS RSP-2009/0476A patent/RS50996B/sr unknown
- 2005-12-20 DK DK05855526T patent/DK1838677T3/da active
- 2005-12-20 PT PT05855526T patent/PT1838677E/pt unknown
- 2005-12-20 EP EP09011453A patent/EP2149562A1/fr not_active Withdrawn
- 2005-12-20 BR BRPI0519726A patent/BRPI0519726B8/pt active IP Right Grant
- 2005-12-20 NZ NZ555981A patent/NZ555981A/en not_active IP Right Cessation
- 2005-12-20 PL PL05855526T patent/PL1838677T3/pl unknown
- 2005-12-20 CN CN2005800433929A patent/CN101084193B/zh active Active
- 2005-12-20 US US11/793,473 patent/US8168624B2/en active Active
- 2005-12-20 CA CA2589988A patent/CA2589988C/fr active Active
- 2005-12-20 EA EA201200954A patent/EA201200954A1/ru unknown
- 2005-12-20 WO PCT/US2005/046983 patent/WO2006069363A2/fr active Application Filing
- 2005-12-20 NZ NZ589756A patent/NZ589756A/en not_active IP Right Cessation
- 2005-12-20 SI SI200530839T patent/SI1838677T1/sl unknown
- 2005-12-20 AT AT05855526T patent/ATE442359T1/de active
- 2005-12-20 ME MEP-2009-338A patent/ME01090B/fr unknown
- 2005-12-20 EA EA200701358A patent/EA017894B1/ru unknown
- 2005-12-20 DE DE602005016603T patent/DE602005016603D1/de active Active
- 2005-12-20 ES ES05855526T patent/ES2332009T3/es active Active
- 2005-12-20 CN CN2011103046342A patent/CN102321023A/zh active Pending
- 2005-12-20 KR KR1020077016727A patent/KR101281919B1/ko active IP Right Grant
- 2005-12-20 EP EP10010048.6A patent/EP2327698B1/fr active Active
- 2005-12-20 AU AU2005318959A patent/AU2005318959B2/en active Active
-
2007
- 2007-06-11 IL IL183844A patent/IL183844A/en active IP Right Grant
- 2007-06-15 CU CU20070138A patent/CU20070138A7/es unknown
- 2007-06-20 ZA ZA2007/05125A patent/ZA200705125B/en unknown
- 2007-06-20 TN TNP2007000235A patent/TNSN07235A1/fr unknown
- 2007-06-21 NI NI200700160A patent/NI200700160A/es unknown
- 2007-07-12 MA MA30070A patent/MA29147B1/fr unknown
- 2007-10-16 HK HK07111117.8A patent/HK1102812A1/xx unknown
-
2009
- 2009-11-10 CY CY20091101162T patent/CY1109599T1/el unknown
- 2009-12-02 HR HR20090640T patent/HRP20090640T1/hr unknown
-
2011
- 2011-10-27 HK HK11111630.0A patent/HK1157334A1/xx unknown
-
2012
- 2012-03-21 US US13/425,669 patent/US8697686B2/en active Active
- 2012-05-18 JP JP2012114460A patent/JP5781008B2/ja active Active
- 2012-09-14 US US13/616,887 patent/US8980881B2/en active Active
-
2014
- 2014-06-02 JP JP2014113743A patent/JP2014156490A/ja active Pending
-
2015
- 2015-03-02 US US14/635,146 patent/US20160009654A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29147B1 (fr) | Formes cristallines d'hydrochlorure de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine | |
HUS2100028I1 (hu) | ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére | |
ATE544744T1 (de) | Verfahren zur herstellung von benzoesaure derivaten | |
NO20071888L (no) | Fremgangsmate for a syntetisere 4-aminosubstituerte forbindelser | |
NO326781B1 (no) | Nitrogenholdige aromatiske ringforbindelser | |
ATE452882T1 (de) | Herstellung von quetiapin | |
SI1509517T1 (sl) | Nova sinteza irbesartana | |
AU2002367268A1 (en) | Processes for production of cyclic diamine compounds or salts thereof | |
FR2890959B1 (fr) | Procede de preparation d'une composition de platre. | |
WO2006043175A3 (fr) | Procede de preparation de composes puriques | |
ATE411310T1 (de) | Reinigungsverfahren von moxonidine | |
NO20063299L (no) | Syntese av en polymorf av 4-amino-5-klor-2-metoksy-N-(1-azabisyklo[3.3.1]non-4-yl)benzamidhydrokloridhydrat | |
WO2001070744A3 (fr) | Procede de preparation de midazolame | |
DE602005012365D1 (de) | Verfahren zur synthese von n-ä3-(3-cyanopyrazoloä1,5aüpyrimidin-7-yl)-phenylü-n-ethylacetamid | |
ATE522499T1 (de) | Verfahren zur herstellung von tamsulosin und seinen derivaten | |
CY1107067T1 (el) | Αλατα δικαρφοξυλικου οξεως της βεναζεπριλης και παρασκευη της βεναζεπριλης μεσω αυτων | |
HUP0204401A2 (hu) | Eljárás 2,6-diklórfenol-vegyületek előállítására |